Market Report Source

Overview

The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry. With developed markets expected to witness aging demographics as well as continued increases in health awareness, disposable incomes and pharmaceutical branding activity, conditions appear highly favourable for further growth.

Lifestyle Drugs Market Outlook is a new report published by Business Insights that provides a detailed analysis of seven individual lifestyle drug markets through the stages of drug delivery and discovery to product launch and lifecycle management. Key industrial trends in the fields of consumer demand and pipeline development are examined, leading players and products within each treatment area are profiled and the market potential of each lifestyle therapy is assessed. This report will also provide a substantial review of reimbursement policies within the seven major markets and their impact upon product sales.

Some Key Findings from this Report:

• The global oral contraceptive market was worth $4378.7m in 2006, of which US sales accounted for 74.7%. The market leader Yasmin controlled 17% of global sales during this period, with an innovative formulation, positive side-effect profile and extended indication approval helping it to overcome high levels of competition.
• The European and US markets for skincare had a combined value of $6590m in 2006, and are projected to reach $8486m by 2011.
• Pfizer’s Champix controlled over 50% of global revenues for smoking cessation therapies by Q2 2007, despite a 2006 launch. This rapid success has been attributed to the drug’s novel formulation, high compliancy, proven efficacy and successful promotional launch.
• The worldwide erectile dysfunction market was worth $3203.6m in 2006, with Pfizer’s Viagra commanding a share of over 50%. Viagra sales have been falling since 2003 and will continue declining until patent expiry in 2013, however direct competition from PDE-5 inhibitors is unlikely due to Viagra’s strong brand and patent strength.
• Anti-ageing products comprise the fastest growing sector of the worldwide cosmeceutical market. Skincare products lead the market, accounting for 80% of total US and European cosmeceutical sales.

Key Issues Examined in this Report:

• Reimbursement. Healthcare providers are under mounting pressure to provide patient reimbursement for the cost of lifestyle drugs, particularly for anti-obesity and smoking cessation therapies. The increasingly prohibitive costs of reimbursement for related conditions have triggered the proposed policy changes.

• Disease classification. As lifestyle conditions increasingly become recognized as treatable diagnoses, the clarification of diagnostic criterion is accelerating the development of targeted treatments

• Demographics. Aging populations and rising disposable incomes in developed countries are expected to have a positive impact on lifestyle therapy revenues as consumers become more informed and financially able to treat symptoms associated with lifestyle diseases.

• Chronic therapy use. With many lifestyle conditions requiring long-term therapy commitments for optimal results, organizations are striving to develop safer and more affordable drugs that can improve levels of patient compliance.

Top Five Reasons to Order:

• Assess the market potential of key lifestyle therapies with this report’s detailed analysis of demand and epidemiology for conditions such as Alcohol Dependence, Alopecia, Obesity, Oral Contraception Sexual Dysfunction, Skin Aging and Smoking Cessation.

• Understand the major issues affecting lifestyle drug revenues across global markets with this report’s examination of consumer spend dynamics and current pricing and reimbursement environments in countries including Japan, France, Germany, Italy, Spain, Canada, Australia, China, the US and the UK.

• Identify key success factors within the lifestyle drugs market by benchmarking the successful growth strategies of leading drug developers and technological innovators.

• Anticipate future trends and scenarios with in-depth analysis of the main drivers and resistors to market growth in addition to the latest innovations in lifestyle drug development, dosing and delivery.

• Evaluate the best methods of obtaining reimbursement and recognition for lifestyle drugs with this report’s comprehensive review of strategic options across the seven major markets.

Table of Contents

Executive Summary
Introduction
Alcohol Dependence
Alopecia
Obesity
Oral Contraception
Sexual Dysfunction
Skin Aging
Smoking Cessation

Chapter 1 Introduction
Summary
Introduction
Defining the Market
Defining Lifestyle Conditions
Social Characteristics
Disease characteristics
Product Characteristics
Sales Potential
High demand upon launch
Ability to create new markets
Drivers of demand for lifestyle drugs
An aging population
Growth in disposable income
Increasing consumer awareness
Rise in branding activities
Barriers to market growth
Demonstrating favorable health economics to payors – the road to rationing
Drug abuse and misuse
Loss of corporate control over brand
Reimbursement
Recommendations for securing reimbursement of lifestyle drugs
Data Caveats

Chapter 2 Alcohol Dependence
Summary
Overview of Alcohol Dependence
Diagnosis
Measuring & Diagnosing
Pathophysiology
Factors Influencing Severity of Symptoms
Gender Influence
Genetic Influence
Prevalence
Reimbursement
Drug Therapy
Disulfiram (Aldehyde Dehydrogenase Inhibitor)
Naltrexone
Benzodiazepines
Sodium Oxybate
Acamprosate
Metadoxine
Market Analysis
Campral (Acamprosate)
Antabuse
Naltrexone Therapies
Pipeline Outlook

Chapter 3 Alopecia
Summary
Overview of Alopecia
Pathophysiology & Etiology
Alopecia areata
Androgenetic alopecia
Anagen effluvium
Telogen effluvium
Scarring alopecia
Self-induced alopecia
Other causes
Prevalence
Drug Therapy
Market Analysis
Propecia
Rogaine (minoxidil)
Pipeline Outlook

Chapter 4 Obesity
Summary
Overview of Obesity
Definition
Measuring & Diagnosing Obesity
Pathophysiology & etiology
Factors influencing severity of Obesity
Age and Gender Influence
Genetic Influence
Nutritional Influence
Prevalence
Reimbursement
Drug Therapy
Market Analysis
Xenical
Reductil/Meridia/Ectiva (sibutramine)
Acomplia (Rimobant)
Company Analysis
Pipeline Outlook
Novel Mechanisms

Chapter 5 Oral Contraception
Summary
Overview of Oral Contraception
The female reproductive population
Drug therapy
Side Effect Profile
Market Analysis
The Yasmin Franchise
Ortho Tri-cyclen Lo
Estrostep Fe
Ortho Evra
Mirena
Seasonale
Reimbursement
Promotional Spend
Company Analysis
Pipeline Outlook

Chapter 6 Sexual Dysfunction
Summary
Overview of Sexual Dysfunction
Male Sexual Dysfunction
Diagnosis
Pathophysiology & diagnostic indicators
Erectile dysfunction (ED)
Loss of libido
Priapism
Peyronie’s disease
Premature and delayed ejaculation
Contributing Factors
Prevalence
Reimbursement
Drug Therapy
PDE-5 Inhibitors
Alprostadil
Market Analysis
Viagra
Cialis
Levitra
Promotional Spend
Product Pipeline
Delivery Mechanism
Niche Markets
OTC Retail
Phosphodiesterase Inhibitors
Female sexual Dysfunction
Diagnosis
Sexual desire disorders
Female sexual arousal disorder
Sexual orgasmic disorder
Sexual pain disorders
Measuring & diagnosing
Factors influencing the severity of female sexual dysfunction
Genetic Influence
Prevalence
Drug Therapy
Pipeline outlook

Chapter 7 Skin Aging
Summary
Overview of Skin Aging
Pathophysiology and etiology
Factors Driving Demand
Demographic Influence
Personal Appearance Gain
Acceptance of Cosmetic Procedures
Prevalence
Drug Therapy
Market Analysis
Renova (tretinoin)
Retin-A/Retin-A Micro (tretinoin)
Botox (botulinum toxin type A)
Tazarotene
Company Activities
Product Pipeline

Chapter 8 Smoking cessation
Summary
Overview of smoking cessation
Measuring & Diagnosing
Pathophysiology & etiology
Factors influencing smoking cessation
Prevalence
Policy & Reimbursement
Drug Therapy
Nicotine replacement therapy
Antidepressants
Nicotine partial receptor agonists
Market Analysis
Champix/Chantix (US)
Nicotine Replacement Therapies
Zyban
Promotional Spend
Company Analysis
Pipeline Outlook
Opioid Receptor Agonists
Cannabinoid Receptor Antagonists
Clonidine
Nicotine Conjugate Vaccine
Glycine Receptor Antagonist

Chapter 9 Appendix
IMS data
Alcohol Dependence
Alopecia
Obesity
Oral Contraception
Sexual Dysfunction
Smoking Cessation
Pearl Index
Index

List of Figures
Figure 1.1: Defining Lifestyle Drugs
Figure 1.2: The reimbursement decision process
Figure 1.3: Improving reimbursement status of lifestyle drugs: a three-pronged approach
Figure 2.4: Geographic market shares for Alcohol Dependence Drugs by sales revenue, 2006 ($
Figure 2.5: Pipeline for alcohol dependence therapies, 2007
Figure 3.6: Pipeline for alopecia therapies, 2007
Figure 4.7: Geographic market shares for anti-obesity products by sales revenue, 2006 ($m)
Figure 4.8: Pipeline for obesity therapies, 2007
Figure 5.9: Revenues by drug class for prescription oral contraceptives ($m), 2006; EU5, Japan, USA
Figure 5.10: Geographic market sizes for prescription oral contraceptives by sales revenue, 2006 ($m)
Figure 5.11: Promotional spend on top oral contraceptive brands in major markets (EU5, USA), 2006 ($m)
Figure 5.12: Pipeline for oral contraceptives, 2007
Figure 6.13: Geographic market size for erectile dysfunction products by sales revenue, 2006, $m
Figure 6.14: Pipeline for erectile dysfunction therapies, 2007
Figure 6.15: Possible caused of female sexual dysfunction
Figure 6.16: Pipeline for female sexual dysfunction therapies, 2007
Figure 7.17: Factors influencing cosmeceutical consumption across the major markets
Figure 7.18: Demographics of skin aging concerns
Figure 7.19: Pipeline for skin aging therapies, 2007
Figure 8.20: Global sales of smoking cessation drugs, 2006 ($m)
Figure 8.21: Pipeline for smoking cessation products, 2007

List of Tables
Table 1.1: Distribution channels covered in IMS MIDAS database
Table 2.2: Top 10 Alcohol dependency therapies 2007, Growth Metrics
Table 2.3: Pipeline analysis; alcohol dependence therapies
Table 3.4: Drug therapy for common types of alopecia
Table 3.5: Top 10 alopecia brands 2007, growth metrics
Table 4.6: Classification of overweight, obesity by BMI, waist circumference and associated disease
Table 4.7: Obesity-linked Genotypes
Table 4.8: Projected prevalence of obesity, 2006-2012 (‘000s)
Table 4.9: Top 10 anti-obesity brands 2007, growth metrics
Table 4.10: Obesity pipeline products
Table 5.11: Forecast growth of the childbearing population; EU5, US and Japan, 2007-10 (000s)
Table 5.12: Top 10 oral contraceptive brands, 2007 ($m)
Table 6.13: Common physiological causes of erectile dysfunction
Table 6.14: Prevalence of moderate and severe ED in the seven major markets
Table 6.15: Top 5 erectile dysfunction brands 2007; growth metrics
Table 6.16: Pipeline analysis; female sexual dysfunction (FSD)
Table 7.17: Symptoms of skin aging
Table 8.18: Factors influencing smoking cessation success
Table 8.19: Smoking prevalence; EU5, US, Japan; 2002
Table 8.20: Top 10 smoking cessation brands 2007, growth metrics